AI and ML Provide Actionable Insights for Intelligent Drug Discovery

Gene therapies, intelligent drug discovery, telemedicine, and the likes are bringing about a change in the life sciences BPO market. Companies in the market for life sciences BPO are innovating through AI and machine learning (ML) for drug discovery. For instance, in June 2019, Navitas Life Sciences— a company that delivers platform-driven clinical solutions and services, announced to partner with ThoughtSphere— a cloud-based clinical data hub and analytics SaaS company, to use AI and ML in order to deliver unparalleled data collection.

The life sciences BPO market is estimated to grow at a favorable CAGR of 7.9% during the forecast period. Companies in the market landscape are increasing their efficiency to develop analytical platforms that offer best-in-class clinical data oversight and actionable insights for faster decision making. Companies in the market for life sciences BPO are using the advantages of AI and ML to deliver improved data collection, while significantly reducing costs involved with mapping highly complex studies.

Proactive and Intelligent Functioning of Pharmaceutical Firms Improve Patient Outcomes

Pharmacovigilance (PV) is shaping the future of the life sciences BPO market. This explains why the revenue of contract research organizations is predicted for aggressive growth during the forecast period and the life sciences BPO market is expected to reach a value of US$ 419.6 Bn by the end of 2027. Pharmaceutical companies in market for life sciences BPO are increasing their R&D activities and clinical trials to ensure drug safety in a patient-centric and digital era where companies are introducing innovative mechanisms to avoid adverse events following a drug’s launch.

Pharmaceutical firms are increasing efforts to engage with patients who are willingly taking ownership of their health outcomes. The life sciences BPO market is witnessing a wave of transformation, as PV is evolving from a regulation-driven, transactional exercise to a more proactive and intelligent model. Such transformations are forming an integral part of the clinical and R&D lifecycle of pharma companies.

Strategic Alliances with Startups Catalyze Growth of Life Sciences BPO Market

The life sciences BPO market is largely fragmented with 10 key players accounting for ~54% of the market share. This indicates that new entrants and startups are giving a tough competition to leading players. Hence, there is a growing need for strategic alliances between big companies and startups to address challenges in the market for life sciences BPO.

As suggested by the Everest Group-a Texas-based management consulting and research firm, as big companies join forces with new entrants, they can cohesively tackle challenges of stagnating growth and stringent regulations with next-gen technology tenets such cognitive computing to improve operational efficiency.

Blockchain and serialization techniques are addressing the issues of counterfeit drugs in the market for life sciences BPO. Several drivers such as data management and virtual trials are offering a big-picture view of clinical results and are speeding up go/no-go decisions. Growing awareness about investments in specialist therapies and personalized medicines are triggering market growth.

RPA Technology Addressing Patient-centricity and Leveraging Medical Drug Research

The robotic process automation (RPA) technology is sweeping the life sciences BPO market. Outsourcing repetitive tasks and manual processes using the RPA technology is anticipated to become increasingly mainstream in developing economies of Asia Pacific. Apart from Asia Pacific, this market in both North America and Europe is estimated to witness growth in terms of revenue during the forecast period. Thus, the RPA technology is expected to generate incremental opportunities for companies in the life sciences BPO market.

The life sciences industry is in its transformative stage where there is a growing need for effective medicines and personalized digital therapeutics that improve quality of life in patients. Hence, companies in the market for life sciences BPO are increasing their focus in the RPA technology and other software robots to provide cognitive automation in medical drug research. Intelligent RPA is helping companies to address patient-centricity and eliminating manual processes. Moreover, AI and ML are helping to optimize processes, streamline costs, and improve care outcomes.

life sciences bpo market segmentation

Analysts’ Viewpoint

Next-gen technologies such as AI and ML are the most prominent drivers for the life sciences BPO market. Data-driven technologies are offering biopharma and medtech organizations with actionable insights and helping them to automate mundane tasks. The recent outbreak of COVID-19 is another key driver generating value-grab opportunities for CROs.

Companies are developing platforms with workflow-enabled issue management that helps clients to lower risks of associated with clinical trials. However, challenges such as the need to rethink customer experience and compliance with industry standards poses as a barrier for market growth. Hence, companies should aim toward blockchain-powered applications to enhance compliance and improve consumer experience.

Life Sciences BPO market: Overview

  • According to Transparency Market Research’s latest research report on the global life sciences BPO market for the historical period from 2017 to 2018 and the forecast period from 2019 to 2027, rise in demand for low cost drugs, patent expirations, and uncertain economic conditions have compelled the pharmaceutical players to take support of various outsourcing services. This is projected to drive the global life sciences BPO market during the forecast period.
  • According to the report, the global life sciences BPO market was valued at ~US$ 214 Bn in 2018 and is anticipated to expand at a CAGR of 7.9% from 2019 to 2027

Technological Advancements in Life Sciences BPO: A Key Driver

  • In the current market scenario, strategic outsourcing services play an important role in addressing various challenges faced by pharmaceutical companies such as stagnant productivity volume, regulatory changes, pricing pressures, and thinner profit margins
  • Strategic outsourcing has become an industry norm and offers a range of services from screening and lead identification to toxicology, pre-clinical studies, clinical trials, manufacturing, and marketing. The pharmaceutical outsourcing market, particularly CMOs and CROs, has evolved in the past few years and expected to witness strong growth in the next decade.
  • Outsourcing has become a feasible and beneficial business strategy for pharmaceutical, biotechnology, and life sciences industries, enabling transfer of non-core activities to outsourcing partners in order to focus on distribution networks, competitive advantage, future growth, marketing strategies, and issues imperative for survival. Rise in cost of R&D, decline in productivity, and patent expirations boost the growth of the global life sciences BPO market.

Globalization of Drug Development with Shift of Manufacturing Units from High Cost to Low Cost Regions

  • The continuous changing market dynamics have compelled the pharmaceutical companies to remodel their existing operations. The focus has shifted toward globalization of the drug development process. The global competitive environment has led to streamlining of manufacturing operations, R&D, medical writing, clinical data management, and other processes.
  • Outsourcing the clinical trial process to contract research units facilitates evaluation of drugs in multiple locations in parallel, thereby producing data, which originates from a large and varied patient pool. This is considered one of the major advantages of research outsourcing.
  • Hence, globalization coupled with budget restraints has compelled the drug manufacturers to opt for low cost regions for outsourcing their R&D, clinical trials, and data management services. This in turn is anticipated to boost the global life sciences BPO market during the forecast period.

Stringent Regulatory Approval Processes in Different Countries to Hamper Life Sciences BPO Market

  • Majority of the clinical trials and other research processes are outsourced to various countries simultaneously. These destination countries have different guidelines and regulatory processes related to drugs, filing, and clinical trials.
  • The conduction of multi-location trials of a single drug in different procedures in different countries poses a challenge to pharmaceutical companies, as these have to follow a completely different procedure in each country. This is considered one of the major challenges for research outsourcing in different countries. Therefore, a company prefers to restrict outsourcing to one destination country.

Life Sciences BPO Market: Competition Landscape

  • This report profiles major players operating in the global life sciences BPO market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global life sciences BPO market is highly fragmented, with large number of players in the global market and small-scale players in regional markets. The top four to five players hold major share of the global life sciences BPO market.
    • Prominent players operating in the global life sciences BPO market are 
    • IQVIA
    • Laboratory Corporation of America Holdings
    • Syneos Health, Inc.
    • Parexel International Corporation
    • PRA Health Sciences, Inc.
    • Charles River Laboratories International, Inc.
    • WuXi AppTec Co., Ltd.
    • ICON plc
    • Medpace Holdings, Inc.
    • Pharmaceutical Product Development, LLC.

Life Sciences BPO Market: Key Developments

  • Key players operating in the global life sciences BPO market are engaged in the development and approval of new products, mergers & acquisitions, and collaborations. Major strategies adopted by the key players are likely to fuel the global life sciences BPO market in the next few years. Key developments in the global life sciences BPO market are: 
  • In June 2018, Laboratory Corporation of America Holdings acquired Sciformix Corporation, a scientific process outsourcing company engaged in offering pharmacovigilance and regulatory solutions to biopharmaceutical and medical device companies. The acquisition strengthened the company’s position in the later phases of drug and device development, primarily for post-marketing pharmacovigilance and market access solutions.
  • In September 2017, Laboratory Corporation of America Holdings acquired Chiltern, which became a part of the company’s CDD segment. This acquisition enabled the former to strengthen its position in the global CRO services market.
  • Syneos Health, Inc. entered into several partnerships to consolidate its position in the market and expand its customer base. For instance, in November 2019, the company entered into a partnership with AiCure, an AI and advanced data analytics company, to optimize patient engagement and trial success.
  • The report on the global life sciences BPO market discusses individual strategies, followed by company profiles of manufacturers of life sciences BPO. The competition landscape section has been included in the report to provide readers with a dashboard view and company market share analysis of the key players operating in the global life sciences BPO market.

Life Sciences BPO Market – Segmentation

Service Type

  • Contract Manufacturing Organizations
    • Active Pharmaceutical Ingredients (API)
    • Final Dosage Form
    • Packaging
  • Contract Research Organizations
    • Drug Discovery
    • PreClinical Trials
    • Clinical Trials (I, II, III, IV)
    • Medical Writing
    • Pharmacovigilance
    • Clinical Data Management
    • Regulatory Services
    • Clinical Monitoring
    • Biostatistics
    • Protocol Development
    • Site Management
  • Contract Sales Organizations
  • Others

 

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

Life sciences BPO market to reach a value of US$ 419.6 Bn by the end of 2027

Life sciences BPO market is estimated to grow at a favorable CAGR of 7.9% during 2019 - 2027

Life sciences BPO market is driven by rise in demand for low cost drugs and patent expirations

The contract manufacturing organizations segment dominated the global life sciences BPO market

Key players in the global life sciences BPO market include IQVIA, Laboratory Corporation of America Holdings, Syneos Health, Inc., Parexel International Corporation, PRA Health Sciences, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Life Sciences BPO Market 

4. Market Overview

    4.1. Introduction

        4.1.1.  Industry Evolution/ Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

    4.4. Global Life Sciences BPO Market Analysis and Forecast, 2017–2027

5. Market Outlook

    5.1. List of Key market players in CMO and CRO

    5.2. Regulatory Scenario, by Region/Global

    5.3. Global Clinical Trials Analysis

    5.4. Key Mergers & Acquisitions

6. Global Life Sciences BPO Market Analysis and Forecast, by Service Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Service Type, 2017–2027

        6.3.1.  Contract Manufacturing Organizations

            6.3.1.1. Active Pharmaceutical Ingredients

            6.3.1.2. Final Dosage Form

            6.3.1.3. Packaging

        6.3.2.  Contract Research Organizations

            6.3.2.1. Drug Discovery

            6.3.2.2. PreClinical Trials

            6.3.2.3. Clinical Trials (I, II, III, IV)

            6.3.2.4. Medical Writing

            6.3.2.5. Pharmacovigilance

            6.3.2.6. Clinical Data Management

            6.3.2.7. Regulatory Services

            6.3.2.8. Clinical Monitoring

            6.3.2.9. Biostatistics

            6.3.2.10. Protocol Development

            6.3.2.11. Site Management

        6.3.3.  Contract Sales Organizations (CSO)

    6.4.  Market Attractiveness Analysis, by Service Type

7. Global Life Sciences BPO Market Analysis and Forecast, by Region

    7.1. Key Findings / Developments

    7.2. Market Value Forecast, by Region, 2017–2027

        7.2.1. North America

        7.2.2. Europe

        7.2.3. Asia Pacific

        7.2.4. Latin America

        7.2.5. Middle East & Africa

    7.3. Market Attractiveness Analysis, by Region

8. North America Life Sciences BPO Market Analysis and Forecast

    8.1. Key Findings

    8.2. Market Value Forecast, by Service Type, 2017–2027

        8.2.1. Contract Manufacturing Organizations

            8.2.1.1. Active Pharmaceutical Ingredients

            8.2.1.2. Final Dosage Form

            8.2.1.3. Packaging

        8.2.2.  Contract Research Organizations

            8.2.2.1. Drug Discovery

            8.2.2.2. PreClinical Trials

            8.2.2.3. Clinical Trials (I, II, III, IV)

            8.2.2.4. Medical Writing

            8.2.2.5. Pharmacovigilance

            8.2.2.6. Clinical Data Management

            8.2.2.7. Regulatory Services

            8.2.2.8. Clinical Monitoring

            8.2.2.9. Biostatistics

            8.2.2.10. Protocol Development

            8.2.2.11. Site Management

        8.2.3.  Contract Sales Organizations (CSO)

    8.3. Market Value Forecast, by Country, 2017–2027

        8.3.1. U.S.

        8.3.2. Canada

    8.4. Market Attractiveness Analysis 

        8.4.1. By Service Type

        8.4.2. By Country

9. Europe Life Sciences BPO Market Analysis and Forecast

    9.1. Key Findings

    9.2. Market Value Forecast, by Service Type, 2017–2027

        9.2.1. Contract Manufacturing Organizations

            9.2.1.1. Active Pharmaceutical Ingredients

            9.2.1.2. Final Dosage Form

            9.2.1.3. Packaging

        9.2.2. Contract Research Organizations

            9.2.2.1. Drug Discovery

            9.2.2.2. PreClinical Trials

            9.2.2.3. Clinical Trials (I, II, III, IV)

            9.2.2.4. Medical Writing

            9.2.2.5. Pharmacovigilance

            9.2.2.6. Clinical Data Management

            9.2.2.7. Regulatory Services

            9.2.2.8. Clinical Monitoring

            9.2.2.9. Biostatistics

            9.2.2.10. Protocol Development

            9.2.2.11. Site Management

        9.2.3.  Contract Sales Organizations (CSO)Market Value Forecast, 2017–2027

    9.3.  Market Attractiveness Analysis, by Country/Sub-region, 2017–2027

        9.3.1. Germany

        9.3.2. U.K.

        9.3.3. France

        9.3.4. Italy

        9.3.5. Spain

        9.3.6. Rest of Europe

    9.4. Market Attractiveness Analysis

        9.4.1. By Service Type 

        9.4.2. By Country/Sub-region

10. Asia Pacific Life Sciences BPO Market Analysis and Forecast

    10.1. Key Findings

    10.2. Market Value Forecast, by Service Type, 2017–2027

        10.2.1. Contract Manufacturing Organizations

            10.2.1.1. Active Pharmaceutical Ingredients

            10.2.1.2. Final Dosage Form

            10.2.1.3. Packaging

        10.2.2. Contract Research Organizations

            10.2.2.1. Drug Discovery

            10.2.2.2. PreClinical Trials

            10.2.2.3. Clinical Trials (I, II, III, IV)

            10.2.2.4. Medical Writing

            10.2.2.5. Pharmacovigilance

            10.2.2.6. Clinical Data Management

            10.2.2.7. Regulatory Services

            10.2.2.8. Clinical Monitoring

            10.2.2.9. Biostatistics

            10.2.2.10. Protocol Development

            10.2.2.11. Site Management

        10.2.3.  Contract Sales Organizations (CSO)Market Value Forecast, 2017–2027

    10.3.  Market Attractiveness Analysis, by Country/Sub-region, 2017–2027

        10.3.1. Australia & New Zealand

        10.3.2. Japan

        10.3.3. China

        10.3.4. India

        10.3.5. Rest of Asia Pacific

    10.4. Market Attractiveness Analysis

        10.4.1. By Service Type 

        10.4.2. By Country/Sub-region

11. Latin America Life Sciences BPO Market Analysis and Forecast

    11.1. Key Findings

    11.2. Market Value Forecast, by Service Type, 2017–2027

        11.2.1. Contract Manufacturing Organizations

            11.2.1.1. Active Pharmaceutical Ingredients

            11.2.1.2. Final Dosage Form

            11.2.1.3. Packaging

        11.2.2. Contract Research Organizations

            11.2.2.1. Drug Discovery

            11.2.2.2. PreClinical Trials

            11.2.2.3. Clinical Trials (I, II, III, IV)

            11.2.2.4. Medical Writing

            11.2.2.5. Pharmacovigilance

            11.2.2.6. Clinical Data Management

            11.2.2.7. Regulatory Services

            11.2.2.8. Clinical Monitoring

            11.2.2.9. Biostatistics

            11.2.2.10. Protocol Development

            11.2.2.11. Site Management

        11.2.3. Contract Sales Organizations (CSO)Market Value Forecast, 2017–2027

    11.3. Market Attractiveness Analysis, by Country/Sub-region, 2017–2027

        11.3.1. Brazil

        11.3.2. Mexico

        11.3.3. Rest of Latin America

    11.4. Market Attractiveness Analysis

        11.4.1. By Service Type 

        11.4.2. By Country/Sub-region

12. Middle East & Africa Life Sciences BPO Market Analysis and Forecast

    12.1. Key Findings

    12.2. Market Value Forecast, by Service Type, 2017–2027

        12.2.1. Contract Manufacturing Organizations

            12.2.1.1. Active Pharmaceutical Ingredients

            12.2.1.2. Final Dosage Form

            12.2.1.3. Packaging

        12.2.2. Contract Research Organizations

            12.2.2.1. Drug Discovery

            12.2.2.2. PreClinical Trials

            12.2.2.3. Clinical Trials (I, II, III, IV) 

            12.2.2.4. Medical Writing

            12.2.2.5. Pharmacovigilance

            12.2.2.6. Clinical Data Management

            12.2.2.7. Regulatory Services

            12.2.2.8. Clinical Monitoring

            12.2.2.9. Biostatistics

            12.2.2.10. Protocol Development

            12.2.2.11. Site Management

        12.2.3. Contract Sales Organizations (CSO) Market Value Forecast, 2017–2027

    12.3. Market Attractiveness Analysis, by Country/Sub-region, 2017–2027

        12.3.1. GCC Countries

        12.3.2. South Africa

        12.3.3. Rest of Middle East & Africa

    12.4. Market Attractiveness Analysis

        12.4.1. By Service Type 

        12.4.2. By Country/Sub-region

13. Competition Landscape

        13.1. Market Share Analysis, by Company, 2018

        13.2. Company Profiles

            13.2.1. Laboratory Corporation of America Holdings

                13.2.1.1. Company Overview

                13.2.1.2. Company Financials

                13.2.1.3. Growth Strategies

                13.2.1.4. SWOT Analysis

            13.2.2. IQVIA, Inc. 

                13.2.2.1. Company Overview

                13.2.2.2. Company Financials

                13.2.2.3. Growth Strategies

                13.2.2.4. SWOT Analysis

            13.2.3. Syneos Health, Inc. 

                13.2.3.1. Company Overview

                13.2.3.2. Company Financials

                13.2.3.3. Growth Strategies

                13.2.3.4. SWOT Analysis

            13.2.4. Parexel International Corporation 

                13.2.4.1. Company Overview

                13.2.4.2. Company Financials

                13.2.4.3. Growth Strategies

                13.2.4.4. SWOT Analysis

            13.2.5. PRA Health Sciences, Inc.

                13.2.5.1. Company Overview

                13.2.5.2. Company Financials

                13.2.5.3. Growth Strategies

                13.2.5.4. SWOT Analysis

            13.2.6. Charles River Laboratories International, Inc. 

                13.2.6.1. Company Overview

                13.2.6.2. Company Financials

                13.2.6.3. Growth Strategies

                13.2.6.4. SWOT Analysis

            13.2.7. WuXi AppTec Co., Ltd.

                13.2.7.1. Company Overview

                13.2.7.2. Company Financials

                13.2.7.3. Growth Strategies

                13.2.7.4. SWOT Analysis

            13.2.8. ICON plc

                13.2.8.1. Company Overview

                13.2.8.2. Company Financials

                13.2.8.3. Growth Strategies

                13.2.8.4. SWOT Analysis

            13.2.9. Medpace Holdings, Inc. 

                13.2.9.1. Company Overview

                13.2.9.2. Company Financials

                13.2.9.3. Growth Strategies

                13.2.9.4. SWOT Analysis

            13.2.10. Pharmaceutical Product Development, LLC. 

                13.2.10.1. Company Overview

                13.2.10.2. Company Financials

                13.2.10.3. Growth Strategies

                13.2.10.4. SWOT Analysis

List of Tables

Table 01: CROs - Heat Map Analysis

Table 02: CROs - Business Models

Table 03: Global Life Sciences BPO Market Value (US$ Bn) Forecast, by Service Type, 2017–2027

Table 04: Global Life Sciences BPO Market Value (US$ Bn) Forecast, by Contract Manufacturing Organizations (CMO), 2017–2027

Table 05: Global Life Sciences BPO Market Value (US$ Bn) Forecast, by Contract Research Organizations (CRO), 2017–2027

Table 06: Global Life Sciences BPO Market Value (US$ Bn) Forecast, by Region, 2017–2027

Table 07: North America Life Sciences BPO Market Value (US$ Bn) Forecast, by Country, 2017–2027

Table 08: North America Life Sciences BPO Market Value (US$ Bn) Forecast, by Service Type, 2017–2027

Table 09: North America Life Sciences BPO Market Value (US$ Bn) Forecast, by Contract Manufacturing Organizations (CMO), 2017–2027

Table 10: North America Life Sciences BPO Market Value (US$ Bn) Forecast, by Contract Research Organizations (CRO), 2017–2027

Table 11: Europe Life Sciences BPO Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027

Table 12: Europe Life Sciences BPO Market Value (US$ Bn) Forecast, by Service Type, 2017–2027

Table 13: Europe Life Sciences BPO Market Value (US$ Bn) Forecast, by Contract Manufacturing Organizations (CMO), 2017–2027

Table 14: Europe Life Sciences BPO Market Value (US$ Bn) Forecast, by Contract Research Organizations (CRO), 2017–2027

Table 15: Asia Pacific Life Sciences BPO Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027

Table 16: Asia Pacific Life Sciences BPO Market Value (US$ Bn) Forecast, by Service Type, 2017–2027

Table 17: Asia Pacific Life Sciences BPO Market Value (US$ Bn) Forecast, by Contract Manufacturing Organizations (CMO), 2017–2027

Table 18: Asia Pacific Life Sciences BPO Market Value (US$ Bn) Forecast, by Contract Research Organizations (CRO), 2017–2027

Table 19: Latin America Life Sciences BPO Market Value (US$ Bn) Forecast, by Country, 2017–2027

Table 20: Latin America Life Sciences BPO Market Value (US$ Bn) Forecast, by Service Type, 2017–2027

Table 21: Latin America Life Sciences BPO Market Value (US$ Bn) Forecast, by Contract Manufacturing Organizations (CMO), 2017–2027

Table 22: Latin America Life Sciences BPO Market Value (US$ Bn) Forecast, by Contract Research Organizations (CRO), 2017–2027

Table 23: Middle East & Africa Life Sciences BPO Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027

Table 24: Middle East & Africa Life Sciences BPO Market Value (US$ Bn) Forecast, by Service Type, 2017–2027

Table 25: Middle East & Africa Life Sciences BPO Market Value (US$ Bn) Forecast, by Contract Manufacturing Organizations (CMO), 2017–2027

Table 26: Middle East & Africa Life Sciences BPO Market Value (US$ Mn) Forecast, by Contract Research Organizations (CRO), 2017–2027

List of Figures

Figure 01: Healthcare Contract Research Outsourcing Market Snapshot

Figure 02: Global Life Sciences BPO Services Market Value (US$ Bn) and Distribution (%), by Region, 2019 and 2027

Figure 03: Global Life Sciences BPO Market Value (US$ Bn) Forecast, 2017–2027

Figure 04: Global Life Sciences BPO Market Value Share (%), by Service Type, 2018

Figure 05: Global Life Sciences BPO Market Value Share (%), by Therapeutic Indication, 2018

Figure 06: Global Life Sciences BPO Market Value Share (%), by End-user, 2018

Figure 07: Global Life Sciences BPO Market Value Share (%), by Region, 2018

Figure 08: Regulatory Scenario - North America

Figure 09: Regulatory Scenario - Europe

Figure 10: Regulatory Scenario - Asia Pacific 

Figure 11: Number of Registered Studies, by Location

Figure 12: Number of Registered Studies, by Intervention

Figure 13: Life Sciences BPO Market - Key Mergers and Acquisitions

Figure 14: CROs- Pricing Strategies 

Figure 15: Key Strategies - Laboratory Corporation of America Holdings (LabCorp) 

Figure 16: Key Strategies - IQVIA 

Figure 17: Global Life Sciences BPO Market Value Share Analysis, by Service Type, 2018 and 2027

Figure 18: Global Life Sciences BPO Market Attractiveness Analysis, by Service Type, 2019?2027

Figure 19: Global Life Sciences BPO Market Value Share Analysis, by CMO, 2018 and 2027

Figure 20: Global Life Sciences BPO Market Attractiveness Analysis, by CMO, 2019?2027

Figure 21: Global Life Sciences BPO Market Attractiveness Analysis, by CRO, 2019?2027

Figure 22: Global Life Sciences BPO Market Attractiveness Analysis, by CRO, 2019?2027

Figure 23: Global Life Sciences BPO Market Value (US$ Bn) and Forecast, by Contract Manufacturing Organizations (CMO), 2017–2027

Figure 24: Global Life Sciences BPO Market Value (US$ Bn) and Forecast, by Contract Research Organizations (CRO), 2017–2027

Figure 25: Global Life Sciences BPO Market Value (US$ Bn) and Forecast, by Contract Sales Organizations (CSO), 2017–2027

Figure 26: Global Life Sciences BPO Market Value (US$ Bn) and Forecast, by Consulting Services, 2017–2027

Figure 27: Global Life Sciences BPO Market Value (US$ Bn) and Forecast, by Active Pharmaceutical Ingredient (API), 2017–2027

Figure 28: Global Life Sciences BPO Market Value (US$ Bn) and Forecast, by Final Dosage Form (FDF) Manufacturing, 2017–2027

Figure 29: Global Life Sciences BPO Market Value (US$ Bn) and Forecast, by Packaging, 2017–2027

Figure 30: Global Life Sciences BPO Market Value (US$ Bn) and Forecast, by Drug Discovery, 2017–2027

Figure 31: Global Life Sciences BPO Market Value (US$ Bn) and Forecast, by PreClinical Trials, 2017–2027

Figure 32: Global Life Sciences BPO Market Value (US$ Bn) and Forecast, by Clinical Trials (I, II, III, IV), 2017–2027

Figure 33: Global Life Sciences BPO Market Value (US$ Bn) and Forecast, by Medical Writing, 2017–2027

Figure 34: Global Life Sciences BPO Market Value (US$ Bn) and Forecast, by Pharmacovigilance, 2017–2027

Figure 35: Global Life Sciences BPO Market Value (US$ Bn) and Forecast, by Clinical Data Management, 2017–2027

Figure 36: Global Life Sciences BPO Market Value (US$ Bn) and Forecast, by Regulatory Services, 2017–2027

Figure 37: Global Life Sciences BPO Market Value (US$ Bn) and Forecast, by Clinical Monitoring, 2017–2027

Figure 38: Global Life Sciences BPO Market Value (US$ Bn) and Forecast, by Biostatistics, 2017–2027

Figure 39: Global Life Sciences BPO Market Value (US$ Bn) and Forecast, by Protocol Development, 2017–2027

Figure 40: Global Life Sciences BPO Market Value (US$ Bn) and Forecast, by Site management, 2017–2027

Figure 41: Life Sciences BPO Market: Regional Outlook

Figure 42: Global Life Sciences BPO Market Value (US$ Bn) Forecast, 2017–2027

Figure 43: Global Life Sciences BPO Market Value Share Analysis, by Region, 2018 and 2027

Figure 44: Global Life Sciences BPO Market Attractiveness Analysis, by Region, 2019-2027

Figure 45: North America Life Sciences BPO Market Value (US$ Bn) Forecast, 2017–2027

Figure 46: North America Life Sciences BPO Market Attractiveness Analysis, by Country, 2019–2027

Figure 47: North America Life Sciences BPO Market Value Share Analysis, by Country, 2018 and 2027

Figure 48: North America Life Sciences BPO Market Value Share Analysis, by Service Type, 2018 and 2027

Figure 49: North America Life Sciences BPO Market Attractiveness Analysis, by Service Type, 2019?2027

Figure 50: Europe Life Sciences BPO Market Value (US$ Bn) Forecast, 2017–2027

Figure 51: Europe Life Sciences BPO Market Attractiveness Analysis, by Country, 2019–2027

Figure 52: Europe Life Sciences BPO Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 53: Europe Life Sciences BPO Market Value Share Analysis, by Service Type, 2018 and 2027

Figure 54: Europe Life Sciences BPO Market Attractiveness Analysis, by Service Type, 2019?2027

Figure 55: Asia Pacific Life Sciences BPO Market Value (US$ Bn) Forecast, 2017–2027

Figure 56: Asia Pacific Life Sciences BPO Market Attractiveness Analysis, by Country, 2019–2027

Figure 57: Asia Pacific Life Sciences BPO Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 58: Asia Pacific Life Sciences BPO Market Value Share Analysis, by Service Type, 2018 and 2027

Figure 59: Asia Pacific Life Sciences BPO Market Attractiveness Analysis, by Service Type, 2019?2027

Figure 60: Latin America Life Sciences BPO Market Value (US$ Bn) Forecast, 2017–2027

Figure 61: Latin America Life Sciences BPO Market Attractiveness Analysis, by Country, 2019–2027

Figure 62: Latin America Life Sciences BPO Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 63: Latin America Life Sciences BPO Market Value Share Analysis, by Service Type, 2018 and 2027

Figure 64: Latin America Life Sciences BPO Market Attractiveness Analysis, by Service Type, 2019?2027

Figure 65: Middle East & Africa Life Sciences BPO Market Value (US$ Bn) Forecast, 2017–2027

Figure 66: Middle East & Africa Life Sciences BPO Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 67: Middle East & Africa Life Sciences BPO Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 68: Middle East & Africa Life Sciences BPO Market Value Share Analysis, by Service Type, 2018 and 2027

Figure 69: Middle East & Africa Life Sciences BPO Market Attractiveness Analysis, by Service Type, 2019?2027

Figure 70: Global Life Sciences BPO Market Share, by Company, 2018

Figure 71: Laboratory Corporation of America Holdings Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 72: Laboratory Corporation of America Holdings Breakdown of Net Sales (%), by Geography, 2018

Figure 73: Laboratory Corporation of America Holdings Breakdown of Net Sales (%), by Business Segment, 2018

Figure 74: Laboratory Corporation of America Holdings Selling, General and Administrative Expenses (US$ Mn), 2017 and 2018

Figure 75: IQVIA, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2018

Figure 76: IQVIA, Inc. Breakdown of Net Sales (%), by Region, 2018

Figure 77: IQVIA, Inc. Breakdown of Net Sales (%), by Business Segment, 2018

Figure 78: IQVIA, Inc. Selling, General and Administrative Expenses (US$ Mn), 2017 and 2018

Figure 79: Syneos Health, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2018

Figure 80: Syneos Health, Inc. Breakdown of Net Sales (%), by Region, 2018

Figure 81: Syneos Health, Inc. Breakdown of Net Sales (%), by Business Segment, 2018

Figure 82: Syneos Health, Inc. Selling, General and Administrative Expenses (US$ Mn), 2017 and 2018

Figure 83: PRA Health Sciences, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2018

Figure 84: PRA Health Sciences, Inc. Breakdown of Net Sales (%), by Region, 2018

Figure 85: PRA Health Sciences, Inc. Breakdown of Net Sales (%), by Business Segment, 2018

Figure 86: PRA Health Sciences, Inc. Selling, general and administrative Cost (US$ Mn), 2017 and 2018

Figure 87: Charles River Laboratories International, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2012–2018

Figure 88: Charles River Laboratories International, Inc. Breakdown of Net Sales (%), by Business Segment, 2018

Figure 89: Charles River Laboratories International, Inc. Breakdown of Net Sales (%) by Products & Services, 2016

Figure 90: WuXi AppTec Co., Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 91: WuXi AppTec Co., Ltd. Breakdown of Net Sales (%), by Segment, 2018

Figure 92: WuXi AppTec Co., Ltd. Breakdown of Net Sales (%), by Geography, 2018

Figure 93: ICON PLC Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2018

Figure 94: ICON plc Breakdown of Operating Expenses, 2014–2018 (US$ Mn)

Figure 95: ICON plc Breakdown of Net Sales (%), by Geography, 2018

Figure 96: Medpace Holdings, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 97: Medpace Holdings, Inc. Breakdown of Operating Expenses (US$ Mn), 2017–2018

Figure 98: Medpace Holdings, Inc. Breakdown of Net Revenues (%), by Category, 2018

Figure 99: Medpace Holdings, Inc. Breakdown of Net Service Revenues (%), by Geography, 2018

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Life Sciences BPO Market